Liver Cancer Drugs Market Size, Share & Trends Analysis Report By Therapeutic Class (Targeted Therapy, Immunotherapy), By Country (U.S., Japan, U.K., Germany, Spain, Italy, France), And Segment Forecasts, 2016 - 2022

Table of Contents

Chapter 1 Research Methodology
                 1.1. Information procurement
                 1.2. Information or Data Analysis
                     1.2.1 Market Formulation & Validation
Chapter 2 Executive Summary
Chapter 3 Disease Primer and Epidemiology
                 3.1. Disease Primer
                 3.2. Epidemiology
Chapter 4 Global Liver Cancer Drugs Market Overview
                 4.1 Market by Therapeutic Class
                 4.2 Market Size and Forecast 2016 - 2022
                 4.3 Market Share Distribution, by Company 2016 - 2022
                 4.4 Market Dynamics and Brand Strategies
                 4.5 Patent Expiry Analysis
                 4.6 Liver Cancer Market: Drivers and Restraints
                     4.6.1 Drivers
                     4.6.2 Challenges
                 4.7 M&A, Deal Landscape (2013 - 2017 YTD)
                     4.7.1 Mergers & Acquisitions
                     4.7.2 Deals Landscape
                 4.8 Emerging Markets
                 4.9 Reimbursement Scenario
                 4.10 Liver Cancer Sector SWOT
Chapter 5 Liver Cancer Market: Pipeline Intelligence
                 5.1. Pipeline Landscape
                     5.1.1 Leading Drugs in Development
                     5.1.2 Key R&D Trends
                 5.2 Pipeline Landscape
                     5.2.1 Late Stage Pipeline and Sales Forecast
                     5.2.2 Profiles of Disruptive Drugs
                 5.3 Global Pipeline Forecast
Chapter 6 Company Profiles
                 6.1 Bayer
                     6.1.1 Company Overview
                     6.1.2 Current Product Portfolio
                     6.1.3 Product Forecast Sales Through 2022
                     6.1.4 Strategic Initiatives
                         6.1.4.1 Key Company News Flow
                     6.1.5 Pipeline Analysis & Overview
                     6.1.6 SWOT
                 6.2 Bristol-Myers Squibb
                     6.2.1 Company Overview
                     6.2.2 Current Product Portfolio
                     6.2.3 Product Forecast Sales Through 2022
                     6.2.4 Strategic Initiatives
                         6.2.4.1 Key Company News Flow
                     6.2.5 Pipeline Analysis & Overview
                     6.2.6 SWOT
                 6.3 Eisai
                     6.3.1 Company Overview
                     6.3.2 Current Product Portfolio
                     6.3.3 Product Forecast Sales Through 2022
                     6.3.4 Strategic Initiatives
                         6.3.4.1 Key Company News Flow
                     6.3.5 Pipeline Analysis & Overview
                     6.3.6 SWOT
                 6.4 Exelixis
                     6.4.1 Company Overview
                     6.4.2 Current Product Portfolio
                     6.4.3 Product Forecast Sales Through 2022
                     6.4.4 Strategic Initiatives
                         6.4.4.1 Key Company News Flow
                     6.4.5 Pipeline Analysis & Overview
                     6.4.6 SWOT
                 6.5 Merck
                     6.5.1 Company Overview
                     6.5.2 Current Product Portfolio
                     6.5.3 Product Forecast Sales Through 2022
                     6.5.4 Strategic Initiatives
                         6.5.4.1 Key Company News Flow
                     6.5.5 Pipeline Analysis & Overview
                     6.5.6 SWOT
Chapter 7 Market Outlook
                 7.1 What the Future Holds
                 7.2 The Winners and Losers
                     7.2.1 Winners
                     7.2.2 Losers
                 7.3 Emerging Companies & Technology Platforms
                 7.4 The Road Ahead

List of Tables

TABLE 1 Marketed Drugs for Liver Cancer
TABLE 2 Sales Performance by Therapeutic Class, 2016 - 22 I
TABLE 3 Sales Performance by Geographic Market, in $ million, 2016 - 22
TABLE 4 U.S. Patents for Current Liver Cancer Drugs
TABLE 5 R&D Pipeline Overview
TABLE 6 Gene Therapy Pipeline
TABLE 7 Late Stage Pipeline
TABLE 8 Lenvima
TABLE 9 Cabometyx
TABLE 10 Keytruda
TABLE 11 Cyramza
TABLE 12 Pexa - Vec (JX - 594)
TABLE 13 Pipeline Forecast of Leading Drugs
TABLE 14 Bayer Sales Forecast, 2016 - 2022
TABLE 15 Bayer Pipeline
TABLE 16 Bristol - Myers Squibb Sales Forecast, 2016 - 2022
TABLE 17 Bristol - Myers Squibb Pipeline
TABLE 18 Eisai Sales Forecast, 2016 - 2022
TABLE 19 Exelixis Sales Forecast, 2016 - 2022
TABLE 20 Exelixis Pipeline
TABLE 21 Merck Sales Forecast, 2016 - 2022 N

List of Figures

FIG. 1 Market research process
FIG. 2 Information Procurement
FIG. 3 Primary research pattern
FIG. 4 Market research approaches
FIG. 5 Value chain based sizing & forecasting
FIG. 6 QFD modelling for market share assessment
FIG. 7 Incidence and Mortality Rate of Liver Cancer per 100,000 in the U.S. (2000 - 12)
FIG. 8 Incidence and Mortality Rate of Liver Cancer per 100,000 in Japan (2000 - 12)
FIG. 9 Incidence and Mortality Rate of Liver Cancer per 100,000 in the U.K. (2000 - 12)
FIG. 10 Incidence and Mortality Rate of Liver Cancer per 100,000 in Spain (2000 - 12)
FIG. 11 Incidence and Mortality Rate of Liver Cancer per 100,000 in France (2000 - 12)
FIG. 12 Incidence and Mortality Rate of Liver Cancer per 100,000 in Italy (2000 - 12)
FIG. 13 Incidence and Mortality Rate of Liver Cancer per 100,000 in Germany (2000 - 12)
FIG. 14 Liver Cancer Market Share, by Therapeutic Class, 2016 - 22
FIG. 15 Regional Market Size, 2016 - 2022
FIG. 16 U.S. Liver Cancer Drugs Market, $ million (2016 - 22)
FIG. 17 Japan Liver Cancer Drugs Market, $ million (2016 - 22)
FIG. 18 Germany Liver Cancer Drugs Market, $ million (2016 - 22)
FIG. 19 France Liver Cancer Drugs Market, $ million (2016 - 22)
FIG. 20 U.K. Liver Cancer Drugs Market, $ million (2016 - 22)
FIG. 21 Italy Liver Cancer Drugs Market, $ million (2016 - 22)
FIG. 22 Spain Liver Cancer Drugs Market, $ million (2016 - 22)
FIG. 23 Liver Cancer Market Share, by Company, 2016 - 22
FIG. 24 Incidence and Mortality Rate of Liver Cancer per 100,000 in China (2000 - 12)
FIG. 25 Liver Cancer Market SWOT
FIG. 26 Bayer HCC Sales Forecast
FIG. 27 Bayer SWOT Analysis
FIG. 28 Bristol - Myers Squibb HCC Sales Forecast
FIG. 29 Bristol - Myers Squibb SWOT Analysis
FIG. 30 Eisai HCC Sales Forecast
FIG. 31 Eisai SWOT Analysis
FIG. 32 Exelixis HCC Sales Forecast
FIG. 33 Exelixis SWOT Analysis
FIG. 34 Merck HCC Sales Forecast
FIG. 35 Merck SWOT Analysis